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Abstract
Aim This article seeks to highlight the methodological
issues involved in the public health economics of vaccines
in the Netherlands and the ensuing implications for
immunisation policy.
Subjects and methods We review and analyse the role of
health economics (and especially cost-effectiveness issues)
in the decision-making process of the Dutch (1) Drugs
Reimbursement System and (2) National Immunisation
Programme. Different types of health-economic analyses
are illustrated by the examples of meningococcal C,
pneumococcal, and human papilloma virus (HPV) vaccines.
Results The role of health economics has recently increased
in importance in Dutch public health decision-making
concerning vaccines. The choice of vaccine strategy against
meningococcus C, the shift in favour of introducing
pneumococcal vaccine, and the prolonged decision on the
reimbursement for HPV vaccine were all related to the
health-economic component in the recommendation process.
Conclusion The role of health economics is growing in
decision-making regarding the reimbursement of new
therapeutic and prophylactic products. Vaccines, like drugs,
will have increasingly to prove their cost-effectiveness if
manufacturers are to lead their product not only from
phases I to IV, but also through to implementation as part of
national immunisation policies covered within national
reimbursement systems.
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Introduction
The role of public health economics and in particular of
cost-effectiveness analysis has been growing in decision-
making regarding the reimbursement of new vaccines in
many countries, including the Netherlands. To the three
traditional hurdles of leading a new vaccine all the way to
licensing (quality analysis and manufacturing, efficacy in
clinical trials, and toxicity and safety assessments) has been
added a fourth, increasingly important one: health-economic
analysis. In the Netherlands, we have recently seen the
importance of the fourth hurdle both for vaccines within the
National Immunisation Programme (NIP) and for manufac-
turers striving to have their vaccine reimbursed within the
Drugs Reimbursement System (“Geneesmiddel Vergoedings
Systeem”, GVS). Respective examples, also to be discussed
below, are the pneumococcal and HPV vaccines.
In this paper, we will illustrate the role of health-
economics analysis in the Netherlands when taking public
health decisions on vaccination policy, where vaccines
recently introduced on the market and/or recently re-visited
due to changing epidemiological situations are concerned.
In particular, vaccines against meningococcus, pneumococ-
cus, hepatitis B virus (HBV), rotavirus (RV), and human
papilloma virus (HPV) have been prominent in Dutch
policy making over the past 5 years. In all cases, specific
health-economic features concerned both the exact meth-
odology applied to estimate cost-effectiveness and the
recommendation/decision provided. The analysis presented
below is specific to the Netherlands, but may serve as a
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useful example for many Western European and North
American countries with regard to the health-economic
assessment.
The Dutch Drugs Reimbursement System
The Dutch Drugs Reimbursement System has included
health-economic analysis as a further criterion for access as
of 1 January 2005 (Rutten 2004). Since that time, newly
registered drugs and vaccines must be able to prove their
cost-effectiveness in addition to their clinical added value.
The system for access to the Drugs Reimbursement System
was clearly initially designed for outpatient drugs rather
than vaccines. Until quite recently, economic analyses for
reimbursement issues have concerned typical outpatient
drugs such as clopidogrel (prevention of arterial disorders),
long-acting risperidone (anti-psychotic drug), oseltamivir
(oral anti-viral drug), long-acting drugs for Attention
Deficiency Hyperactivity Disorder, etc. (Postma et al.
2007b; Heeg et al. 2005, 2007). In all, nearly 30 drugs
now have an economic file included in the reimbursement
process. It is worth noting that reimbursement of such drugs
by the Drugs Reimbursement System is not a straightfor-
ward or simple process, and various manufacturers have
failed to achieve reimbursement for their outpatient drugs.
Designed for the “classical” outpatient drug, the Drugs
Reimbursement System has recently received requests from
vaccine manufacturers to include vaccines on one of the
reimbursement lists (1A, 1B, and list 2, being for clusters of
equivalent drugs, unique drugs with added value, and
additional conditions for reimbursement, respectively). In
particular, these requests concerned vaccines that are not
(yet) part of the NIP, i.e. HPV and RV vaccines.
Neither of the two has yet obtained reimbursement status
nor a positive recommendation for reimbursement within
the Drugs Reimbursement System, which shows just how
arduous it is for a drug/vaccine to be registered on one of
the Drugs Reimbursement System’s lists (www.cvz.nl,
accessed January 20th 2008). In neighbouring countries,
for example, Belgium, positive recommendations for both
vaccines and first arrangements for reimbursements have
existed since 2007 (www.kce.be, accessed 25 April 2008).
Clinical, epidemiological, and also health-economic
considerations all play a role in the reimbursement process.
The whole process is a complex superimposition of advisory
boards composed of specialists and academics: Committee
Pharmaceutical Help (Commissie Farmaceutische Hulp,
Utrecht), the Foundation for Health Care Insurance (College
voor Zorgverzekeringen CvZ, Diemen), and the Ministry of
Public Health, Welfare & Sports (MoH). It is the MoH that
has the last say on reimbursement.
Advisory boards tend to advise along the same lines;
however, this does not always occur, and examples exist
where the advice has differed from one board to the other.
The classic example in the Netherlands is Viagra®, for
which each successive advisory board limited further the
target group for reimbursement such as in the end the MoH
decided not to reimburse the drug at all (Heeg et al. 2007;
www.cvz.nl, accessed 20 January 2008).
National Immunisation Programme (NIP)
Since the turn of the century a separate committee of the
Health Council advises the MoH on the state-of-the-art of
scientific aspects concerning those vaccines within the
Dutch NIP and new vaccines to be considered for the
Programme (www.gr.nl, accessed January 20th 2008).
Within this committee, health economics play a role next
to clinical, epidemiological, ethical, and practical aspects.
On the one hand, the committee provides basic advice: for
example, general criteria for a vaccine to be eligible for the
NIP as a function of disease burden, public health nature of
the infection, and equity. On the other hand, the committee
delivers targeted and timely advice on specific vaccines
under discussion regarding inclusion, exclusion, or substi-
tution in the programme.
To cite a few examples, general recommendations have
been issued and specific reports produced on meningococ-
cus, pneumococcus, pertussis, and HBV vaccines (Health
Council 2002, 2004, 2005, 2007). Related committees have
recently produced reports (or are in the process of doing so)
on influenza vaccination for the elderly and the HPV
vaccines Cervarix® and Gardasil®. Public health-economic
arguments are always largely accounted for when issuing
such recommendations (Postma et al. 2007a).
Vaccine manufacturers may prefer to have their vaccine
included in the NIP, given the large potential market.
However, decision-making concerning the introduction of
new vaccines in the NIP appears to be relatively slow in the
Netherlands. For instance, recent developments in HPV
vaccination indicate that many countries have already
achieved reimbursement within national programmes and
have thus started vaccinating as of 1 January 2008 (Thiry
et al. 2007), whereas the Dutch are still awaiting decisions
concerning HPV and the NIP (situation April 1st 2008).
The route to reimbursement through the Drugs Reim-
bursement System is potentially quicker than that through
the NIP, tempting manufacturers to present their vaccines
preferably to the former institution. As far as the Drugs
Reimbursement System is concerned, the manufacturer is in
a “leading” position since according to the rules and
regulations a full file has to be taken into consideration
and the advisory process on the reimbursement has to be
started up. Furthermore, a decision on reimbursement must
be taken within a limited number of months after the
manufacturer has presented the full reimbursement file to
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the Foundation for Health Care Insurance, including a
health-economic assessment possibly performed or assigned
by the manufacturers themselves.
In the process of seeking reimbursement through the
NIP, on the other hand, the manufacturer is certainly not in
a leading position, as there exist no legal limitations for the
timeframe on issuing of recommendations by the Health
Council.
Another potential delay in the Health Council recom-
mendations process is the request for an independent
health-economics assessment, i.e., one not performed by
the manufacturer or within an assignment by the manufac-
turer. However, the manufacturer may be invited for
hearings and scientific presentations that can speed up the
process.
Method
Types of health-economic analysis
For reimbursement issues, three types of health-economics
analysis are generally distinguished. Table 1 lists these
analyses and some of their characteristic features. Basically,
all types include the costs of the intervention (in this case:
vaccination) and the related monetary savings. Costs of the
intervention should include the initial investment costs of,
for example, infant vaccination, but also possible follow-up
costs, such as providing a booster vaccination to enhance
long-term protection of immunisation. Savings relate to
averted direct health-care costs, but may also relate to
averted indirect non-health-care costs of production losses
(also, vaccination costs may include indirect costs if work
loss is connected to being vaccinated, with influenza
vaccination for healthy working adults as one example)
(Postma et al. 2005). It should likewise be noted that direct
non-health-care costs and savings are included in economic
analyses, reflecting for example travel costs to the health-
care sites. Costs and savings are subtracted from each other
to define net costs.
Major differences between the three methods as listed in
Table 1 relate to the health outcomes considered. In cost-
minimisation analysis, health outcomes are generally not
considered, and the framework is usually used for such
situations only when safety and effectiveness of two drugs/
vaccines are considered equivalent. This type of analysis is
generally insufficient for analysing new vaccines since they
mostly quite obviously have something extra to offer (for
instance HPV, RV, or acellular pertussis vaccines). Cost-
effectiveness analysis typically includes clinical outcomes
averted relating to serious morbidity and/or mortality, e.g.,
complications and deaths averted, end-stage serious disease
delayed, and-directly related to the latter-life-years gained.
Cost-utility analysis includes quality of life as a major
outcome, next to life-years gained. The typical outcome in
which both life-years gained and quality impacts are
integrated is the Quality-Adjusted Life-Year (QALY)
(Postma 2003).
Guidelines
For the adequate conduct of such health-economics
analyses, guidelines for good health-economics practice
have been developed (www.ispor.com, accessed January
20th 2008). The number and exact nature of such guide-
lines differ according to country, but generally guidelines
encompass “rules” for (1) how to conduct and interpret an
incremental analysis, (2) how appropriately to discount
money and health effects, and (3) how to design a model
that incorporates all effects on financial and health out-
comes during the appropriate time horizon (Foundation for
Health Care Insurance 2004).
The guidelines are directly derived from the procedure
for outpatient drugs that has existed in the Netherlands
since 1 January 2005. In particular, it is stated there that a
new drug should be compared in the incremental health-
economic analysis with the best available alternative. Also,
the exact discount rates to be used are specified at 4% for
costs and 1.5% for health effects.
By way of example and with regard to the last “rule”, it
is often stated that dynamic models should be applied to
vaccines in order to include secondary impacts on non-
vaccinated as well as primary impacts on vaccinated
groups. As vaccination generally reduces the spread of an
infectious disease, vaccinating target groups (often infants)
theoretically and practically limits the probability that non-
vaccinated groups become infected, hence the expression
that vaccination provides “herd immunity” to unvaccinated
Table 1 Types of health-economic analysis
Technique Monetary aspects included Clinical aspects included Utility aspects included
Cost-minimisation analysis Costs and savings Not applicable Not applicable
Cost-effectiveness analysis Costs and savings Clinical outcomes and life years Not applicable
Cost-utility analysis Costs and savings Life years Quality of life
Source: Postma 2003
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groups. One example is the protection of the elderly against
invasive pneumococcal disease as a consequence of infant
vaccination programmes (Whitney et al. 2003; Lexau et al.
2005).
Objective
The objective of this paper is to review the role of health-
economic analysis in some of the recent examples in Dutch
decision making on reimbursing new vaccines in either the
Drugs Reimbursement System or NIP, with special refer-
ence to the type of economic analysis and the guidelines.
Results
Meningococcal C vaccine
Dutch decision-makers were provided with cost-effectiveness
information on introducing meningococcal serogroup C
conjugate vaccination (NeisVac and Meningitec) in 2001–
2002, resulting in the introduction of a programme in 2002
directed at 14-month-old infants (Welte et al. 2004). The
analyses were published in Vaccine and typically followed
a rigid incremental approach (Welte et al. 2004). An
incremental approach was required as various scenarios
for vaccinating could be considered. In particular, (1) one-
off vaccination at 14 months, (2) two doses at 5 and
6 months, and (3) three doses very early in infancy (2, 3
and 4 months) were all assumed to provide similar long-
term protection (in the model assumed at 90% effectiveness
for a duration of 20 years, as seen for other conjugate
vaccines). In an aggregate analysis-each scenario in turn being
compared with “doing-nothing”-all scenarios provided ac-
ceptable cost- effectiveness ratios per life-year gained
(Table 2) if we recall that for the Netherlands once a
threshold has been suggested at €20,000 per life-year gained
(Hubben et al. 2007). This might be labelled “the aggregate
approach”, also sometimes referred to as calculating average
cost-effectiveness. However, it was stressed during the
decision-making process that the more accurate comparison
would be the extra costs and extra health gains for one
scenario over the other, rather than comparing with the
“doing-nothing” alternative for all. Since strategies could
easily be ranked according to the number of doses provided
and thus the investment costs required, an important question
arose, namely how many extra costs are entailed in relation
to the extra health gains if providing one or two extra dose(s)
as compared to giving one dose at 14 months? This might be
labelled “the incremental approach” (Table 2, last two
columns). The incremental approach is recommended or
even prescribed in many international guidelines, including
those in the Netherlands. Table 2 clearly indicates that
incremental cost-effectiveness is substantially different from
aggregate cost-effectiveness, and it can be seen that
providing one extra dose as compared to the one-dose
schedule would represent a cost of €101,600 per life-year
gained. Providing even two extra doses over the one-dose
schedule would be still more expensive at €146,900. These
figures were influential in the Dutch final decision to
implement a one-dose meningococcal C vaccination strategy
(Welte et al. 2005).
Pneumococcal vaccine
Introduction of pneumococcal infant vaccination using the
seven-valent vaccine (Prevnar®) has been formally ana-
lysed twice in recent years in the Netherlands. In 2001,
cost-effectiveness was estimated as highly unfavourable at
€82,700 per life-year gained (Bos et al. 2003). Pneumococ-
cal vaccination was not introduced at that time. Recently,
new data have been analysed, and updated estimates of
cost-effectiveness have been provided. A striking decrease
in the cost-effectiveness ratio as compared to the 2001
estimate has been published again in Vaccine (Hubben et al.
2007). In particular, base-case cost-effectiveness was
estimated at €15,600 per life-year gained. With regard to
modifications in the data as compared to the 2001 analysis,
one element clearly appeared as being the most influential.
In 2000–2005, new evidence became available in the US
regarding “herd immunity” effects of pneumococcal infant
vaccination, i.e. how large-scale infant vaccination
decreases invasive pneumococcal infections in elderly
(Whitney et al. 2003; Lexau et al. 2005). The evidence
was considered so convincing that it was included as an
indirect health benefit in the Dutch model. US rates were
implemented in the previously developed (2001) Dutch
model, using straightforward proportional calculus for the
specific serotypes included in the vaccine. Table 3 summa-
rises the model results. It can be seen that the majority of
life-years gained are derived from averted deaths in the
Table 2 Deaths averted (all and incremental) cost-effectiveness ratio
(CER or ICER) in net costs per life year gained (in 2000 €s) for three





14 months 20.5 2,200 NA 2,200*
5 and 6 months 22.1 11,200 1.6** 101,600**
2, 3 and 4 months 22.7 19,900 2.2** 146,900**
*As compared to “do nothing”;
**as compared to “14 months”;
NA=not applicable
Source: Welte et al. 2004
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elderly through indirect protection. With the 2001 estimate
not yet including the herd-immunity effects, the difference
between both estimates for cost-effectiveness of pneumo-
coccal vaccination is readily explained (Hubben et al. 2007).
Finally, Fig. 1 summarises the results showing the cost-
effectiveness outcome for varying discount rates for costs
and life-years gained (the base-case estimate provided
above at €15,600 was evaluated at 4% for both costs and
life years). Discounting is performed to correct for time
preference and generally adjusts all future costs, savings,
and health gains to lower corresponding present-day values.
Cost-effectiveness of vaccines crucially depends on the
exact discount rate applied (Drummond et al. 2007). Figure 1
illustrates that the exact rate for discounting is particularly
crucial for life years. Discussion on the methodology for
discounting exists for health gains, whereas for costs and
savings widespread consensus was achieved many years
ago (Brouwer et al. 2005; Gravelle et al. 2007). In the
Netherlands, for instance, the discount rate for costs at 4%
has been applied for almost a decade. However, for health
gains the Dutch recently changed from 4% to 1.5%, with an
obvious major impact on the cost-effectiveness of vaccines
(Foundation for Health Care Insurance 1999, 2004). As a
result of the decrease in the discount rate for health effects,
Fig. 1 illustrates that the cost-effectiveness ratio for
pneumococcal vaccination decreases from €15,600 to just
over €10,000 per life-year gained.
HPV vaccine
One of the HPV vaccines was evaluated for inclusion in the
Dutch Drugs Reimbursement System based on its thera-
peutic and health-economics characteristics. Gardasil® was
judged to have evident therapeutic added value; however,
the health economics report provided by the manufacturer
was initially considered insufficient in 2007 (www.vcz.nl,
accessed 20 January 2008). The criticism was directed
towards (1) the application of the per-protocol analysis
from the clinical trial rather than the preferred intention-to-
treat analysis as the basis was used for economic analysis
and (2) the inadequate underpinning of some of the major
parameters in the health-economic model, in particular
those related to QALYs and to indirect costs of production
losses.
Cost-utility was estimated for two age groups: 13–
15 year olds and 16–26 year olds. Base-case cost utilities
were estimated at €21,900 and €29,900 per QALY,
respectively, assuming lifetime protection of the vaccine
against serotypes 6, 11, 16, and 18. Also, it was shown that
if the duration of protection was lowered to the 5 years for
which evidence was available, cost utilities would in the
meantime become unacceptably high (in the range of
€70,000–80,000 for both age groups). Despite the fact that
the analysis was performed accounting for the already
lowered discount rate for QALYs at 1.5%, results were still
Table 3 Health outcomes averted for pneumococcal vaccination in
the Netherlands on an annual basis, divided over those protected
through vaccination (infants and children) and those not vaccinated










Life years 385 868
*NA=not assumed
Source: Hubben et al. 2007
Fig. 1 Incremental cost-
effectiveness ratio (ICER) of
pneumococcal vaccination in net
costs (in 2004 €s) per life-year
gained for varying discount rates
for costs (and savings) and
health effects (i.e. life years)
Source: Hubben et al. 2007
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very sensitive for discounting such health gains. In
particular, in the absence of discounting health gains at all
(a rate of 0%), base-case cost-utility ratios were consistently
halved. It is noteworthy that (near) non-discounting of
health gains is still advocated and motivated, in particular
in the area of infectious diseases vaccines (Bos et al. 2004).
The prolonged decision on the reimbursement of the
HPV vaccine within the Dutch Drugs Reimbursement
System is unique in that it is currently the sole product having
so far been denied for the Reimbursement System based
on the health economics report. [Previously, ivabradine was
denied reimbursement based on health-economics arguments.
However, in a re-assessment positive advice on reimburse-
ment has been provided, including a positive opinion on the
health economics report (www.cvz.nl, accessed 20 January
2008)].
Also noteworthy is that the Dutch situation differs from
that of many other countries where the HPV vaccine has
immediately received a positive recommendation for reim-
bursement or has already been incorporated in reimbursement
systems, either Drugs Reimbursement System-like or NIP-
like environments. These countries include amongst others
Belgium, Denmark and Greenland, France, Germany, Italy,
Switzerland, and the UK. Such positive opinions have often
been based on health economics as well. This illustrates that
the Dutch health economics assessments may well differ from
those in other countries regarding the immediate interpreta-
tion of added value of innovative therapeutic and prophylactic
products, such as the HPV vaccine.
Since early April 2008, a formal positive recommenda-
tion to include the HPV vaccine in the Dutch NIP does
exist. In particular, the Health Council advises to vaccinate
12-year-old girls and design a catch-up program (GR
2008). Based on assumed lifetime protection (if needed
with a booster included at the age of 30), cost-utility is
indicated to grossly vary from €20,000 to €30,000 per
QALY, which is in line with the analyses that were
previously done for the GVS for the young teenage girls.
Additionally, it is stated that the design of the catch-up
program should be guided by health-economic outcomes,
which could imply that girls aged 16–18 would not be
included given their risk of already being exposed to the
virus. For those girls falling outside the catch-up, the Health
Council advises the MoH to reconsider reimbursement
within the Drugs Reimbursement System (GR 2008).
Discussion and conclusions
In the Netherlands, two routes exist for the reimbursement
of vaccines; i.e. the Drugs Reimbursement System and the
NIP. Some differences have been discussed going through
the examples provided above. One further aspect regarding
health-economic evidence should also be noted. In partic-
ular, economic analyses in the framework of reimbursement
for the Drugs Reimbursement System are generally done by
the producers themselves (or allied consultancy companies),
whereas those for the NIP are required to be performed by
independent research institutes, such as universities and
public health bureaus. In-house analyses done by the
companies have the advantage of speed; those done by
independent institutes appear to require more time in
practice. For short-term reimbursement-generally with yet
limited use-the Drugs Reimbursement System seems there-
fore very suitable, whereas for universal large-scale use
evaluation within the procedure for NIP seems more suitable.
We have described how the role of health economics has
recently increased in importance in Dutch public health
decision-making concerning vaccines. Health-economic
assessments, as seen above, have been crucial for the
reimbursement of vaccines against meningococcal C, pneu-
mococcal, and HPV infections. Such assessments are partic-
ularly crucial to the Foundation for Health Care Insurance and
the Health Council when making their recommendations to
the MoH. The specific choice of vaccination strategy against
meningococcus C, the shift from deciding against implement-
ing pneumococcal vaccination, and the prolonged decision on
the reimbursement for the quadrivalent HPV vaccine can all
be related to a health-economics component in the recom-
mendation process. Currently, this HPV vaccine is the only
product denied for the Dutch Drugs Reimbursement System
based on the health-economics report.
This paper has outlined the application of guidelines for
health-economics research in the practice of economic
evaluation of vaccines. In particular, the usefulness of a
rigid incremental approach in the analytic design has been
considered for meningococcal C vaccination. Furthermore,
relevance of the specific and adequate model choice has
been shown for the seven-valent pneumococcal vaccine,
where a model specification was chosen to enable inclusion
of “herd immunity” effects. Both the examples of pneumo-
coccal vaccine and the HPV vaccine illustrated the
sensitivity to the discount rate for health gains if vaccines
are evaluated. Discussions on the exact methodologies to be
used for discounting are of great importance in this specific
area of public health.
Finally, we have illustrated the Dutch interpretation of
public health-economic analyses of new vaccines, which
often varies widely from that in other countries. Three
examples are of particular interest. The Dutch one-dose
strategy for meningococcal vaccination was motivated by
health-economic considerations and differs from the choice
in other major countries. The seven-valent pneumococcal
vaccine was introduced in the NIP years after many other
countries had done so. And lastly, the Dutch reserved
position towards introducing HPV vaccination, despite a
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promising health-economics potential, has resulted in a
situation in which the vaccine is not yet reimbursed in the
Netherlands, as opposed to many other countries. However,
a formal positive recommendation of the Health Council
became available early in 2008, and discussions on re-
imbursement have started again, including potential cost-
effectiveness and cost-utility within the NIP.
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